Pandemics of metabolic síndrome, obesity, and type 2 diabetes is a major challenge for the next years and supported the grat burden of cardiovascular diseases. The R3i (Residual Risk Reduction initiative) has previously highlighted atherogenic dyslipidaemia as an important and modifiable contributor to the lipid related residual cardiovascular risk. Atherogenic dyslipidaemia is defined as an imbalance between proatherogenic triglycerides-rich apoB-containing lipoproteins and antiatherogenic AI containing lipoproteins. To improve clinical management of atherogenic dyslipidaemia a despite of lifestyle intervention includes pharmacological approach, and fibrates is the main option for combination with a statin to further reduce non-HDL cholesterol.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.arteri.2014.09.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of SGLT2 Inhibitors on Lipoproteins in Type 2 Diabetes.
Curr Diab Rep
January 2025
Facultad de Farmacia y Bioquímica, Laboratorio de Lípidos y Aterosclerosis, Universidad de Buenos Aires, Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC-UBA), Buenos Aires, Argentina.
Purpose Of Review: This article explores the cardiovascular effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with type 2 diabetes mellitus (T2DM), with a particular focus on their impact on lipid profiles. As evidence grows of the cardiovascular benefits of SGLT2i beyond glucose control, it is essential to better understand their effects on lipoproteins and their impact on cardiovascular disease.
Recent Findings: SGLT2i have shown significant cardiovascular benefits in patients with type 2 diabetes mellitus, beyond their role in lowering blood glucose.
The Effect of Metabolic Bariatric Surgery on Cardiovascular Risks: A Prospective Study Measuring Antibodies to Apolipoprotein A-1.
Obes Surg
January 2025
Cairo University Hospitals, Cairo, Egypt.
Background: Obesity is a chronic disease associated with other associated medical problems, including atherogenic dyslipidemia. Metabolic bariatric surgery (MBS) has been shown to reduce long-term cardiovascular risk (CVR). Anti-ApoA-1 antibodies (AAA1) are independently associated with cardiovascular disease, which remains a major cause of death in individuals with obesity.
View Article and Find Full Text PDFA Narrative Review of the Role of Blood Biomarkers in the Risk Prediction of Cardiovascular Diseases.
Cureus
December 2024
Public Health Sciences, Scientific Knowledge for Ageing and Neurological Ailments (SKAN) Research Trust, Bengaluru, IND.
Article Synopsis
- Cardiovascular disease (CVD) is a major global health issue, making it essential to find biomarkers that can detect it early in healthy people to enhance preventive measures and improve overall health outcomes.
- Various biomarkers, such as atherogenic lipoproteins and inflammatory markers like C-reactive protein (CRP), have shown connections to CVD risk factors, aiding in risk prediction when combined with traditional indicators.
- Emerging biomarkers like myeloperoxidase (MPO) and procalcitonin (PCT) are being explored for their potential in early detection of systemic infections, emphasizing the importance of identifying the best biomarker combinations for effective diagnosis and risk assessment.
The Role of the Atherogenic Index of Plasma and the Castelli Risk Index I and II in Cardiovascular Disease.
Cureus
November 2024
Department of Internal Medicine, M. S. Ramaiah Medical College, Bengaluru, IND.
Introduction: Metabolic syndrome (MS), identified by abdominal obesity, insulin resistance, hypertension, and/or dyslipidemia, occurs across all BMI (body mass index) ranges and increases the risk of atherosclerotic cardiovascular (CV) diseases and type II diabetes. The Atherogenic Index of Plasma (AIP) and Castelli Risk Index (CRI) I & II are ratios that can be calculated from a simple lipid profile test. These ratios are independent risk factors for CV diseases and have been shown to be increased in angiographically confirmed coronary artery disease (CAD) patients.
View Article and Find Full Text PDFThe interplay of factors in metabolic syndrome: understanding its roots and complexity.
Mol Med
December 2024
Center for Cancer Immunology, Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, China.
Metabolic syndrome (MetS) is an indicator and diverse endocrine syndrome that combines different metabolic defects with clinical, physiological, biochemical, and metabolic factors. Obesity, visceral adiposity and abdominal obesity, dyslipidemia, insulin resistance (IR), elevated blood pressure, endothelial dysfunction, and acute or chronic inflammation are the risk factors associated with MetS. Abdominal obesity, a hallmark of MetS, highlights dysfunctional fat tissue and increased risk for cardiovascular disease and diabetes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!